Inhalation pharmacokinetics of 1,3-butadiene and 1,2-epoxybutene-3 in rats and mice.
Studies were conducted on inhalation pharmacokinetics of 1,3-butadiene and of its primary reactive metabolic intermediate 1,2-epoxybutene-3 in rats (Sprague-Dawley) and mice (B6C3F1). Investigations of inhalation pharmacokinetics of 1,3-butadiene revealed saturation kinetics of 1,3-butadiene metabolism in both species. For rats and mice linear pharmacokinetics apply at exposure concentrations below 1000 ppm 1,3-butadiene; saturation of 1,3-butadiene metabolism is observed at atmospheric concentrations of about 2000 ppm. The estimated maximal metabolic elimination rates were 400 mumole/hr/kg for mice and 200 mumole/hr/kg for rats. This shows that 1,3-butadiene is metabolized by mice at about twice the rate of rats. Investigations of inhalation pharmacokinetics of 1,2-epoxybutene-3 revealed major differences in metabolism of this compound between both species. No indication of saturation kinetics of 1,2-epoxybutene-3 metabolism could be observed in rats up to exposure concentrations of 5000 ppm, whereas in mice the saturation of epoxybutene metabolism became apparent at atmospheric concentrations of about 500 ppm. The estimated maximal metabolic rate for 1,2-epoxybutene-3 was 350 mumole/hr/kg in mice and greater than 2600 mumole/hr/kg in rats. When the animals are exposed to high concentrations of 1,3-butadiene, 1,2-epoxybutene-3 is exhaled by rats and mice. For rats 1,2-epoxybutene-3 concentration in the gas phase of the system reaches a plateau at about 4 ppm. For mice, 1,2-epoxybutene-3 concentration increases with exposure time until, at about 10 ppm, signs of acute toxicity are observed. Under these conditions hepatic nonprotein sulfhydryl compounds are virtually depleted in mice but not in rats.(ABSTRACT TRUNCATED AT 250 WORDS)
Laib
R J
RJ
Institut für Arbeitsphysiologie, Abteilung für Toxikologie und Arbeitsmedizin, Dortmund, FRG.
Filser
J G
JG
Kreiling
R
R
Vangala
R R
RR
Bolt
H M
HM
D000280:Administration, Inhalation; D000478:Alkylation; D000818:Animals; D002070:Butadienes / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D002273:Carcinogens / Q000008:administration & dosage / Q000493:pharmacokinetics; D004247:DNA / Q000378:metabolism; D004852:Epoxy Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D004988:Ethers, Cyclic / Q000493:pharmacokinetics*; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D009687:Nuclear Proteins / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D013438:Sulfhydryl Compounds / Q000378:metabolism
D002070:Butadienes; D002273:Carcinogens; D004852:Epoxy Compounds; D004988:Ethers, Cyclic; D009687:Nuclear Proteins; D013438:Sulfhydryl Compounds; C024370:3,4-epoxy-1-butene; D004247:DNA; C031763:1,3-butadiene